Sonoma Pharmaceuticals Inc

Research Sonoma Pharmaceuticals Inc (SNOA) on Bullrun: market cap USD 6.46M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 6.46M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 14.29M-USD 3.46M-USD 168.00K38.2%-2.79USD 5.37MUSD 220.00KUSD 4.41M
FY2024USD 12.74M-USD 4.84M-USD 2.40M37.3%-10.63USD 3.13MUSD 323.00KUSD 6.14M
FY2023USD 13.27M-USD 5.15M-USD 6.42M33.7%-1.52USD 3.82MUSD 431.00KUSD 7.98M
FY2022USD 12.63M-USD 5.09M-USD 4.39M31.6%-1.92USD 7.40MUSD 0USD 8.70M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 6.46Mn/an/an/a
20252025-12-31USD 6.30Mn/an/an/a
20242024-12-31USD 4.35Mn/an/an/a
20232023-12-29USD 2.46Mn/an/an/a
20222022-12-30USD 3.48Mn/an/an/a
20212021-12-31USD 14.14Mn/an/an/a

About Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Sonoma Pharmaceuticals Inc's market cap?

Sonoma Pharmaceuticals Inc's market capitalization is USD 6.46M.

What does Sonoma Pharmaceuticals Inc do?

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.